Rate of response to chemotherapy after refractory disease
. | MDACC (n = 165) . | IA/MC (n = 82) . | LY.12 (CCTG) (n = 219) . | CORAL (LYSARC) (n = 170) . | Pooled* (N = 636) . |
---|---|---|---|---|---|
Patients evaluated for response, n† | 165 | 82 | 106 | 170 | 523 |
Response rate, % (95% CI) | 20 | 26 | 26 | 31 | 26 (21-31) |
CR rate | 7 | 7 | 2 | 15 | 7 (3-15) |
PR rate | 13 | 18 | 25 | 16 | 18 (13-23) |
Response rate by refractory category, % (95% CI) | |||||
Primary refractory | |||||
RR | — | 25 | 27 | 10 | 20 (11-34) |
CR rate | — | 10 | 1 | 2 | 3 (1-11) |
Refractory to second-line or later-line therapy | |||||
RR | 20 | 21 | 20 | 40 | 26 (17-39) |
CR rate | 7 | 5 | 20 | 18 | 10 (5-20) |
Relapse ≤12 mo post-ASCT | |||||
RR | 19 | 35 | — | 39 | 34 (24-45) |
CR rate | 6 | 10 | — | 25 | 15 (6-31) |
. | MDACC (n = 165) . | IA/MC (n = 82) . | LY.12 (CCTG) (n = 219) . | CORAL (LYSARC) (n = 170) . | Pooled* (N = 636) . |
---|---|---|---|---|---|
Patients evaluated for response, n† | 165 | 82 | 106 | 170 | 523 |
Response rate, % (95% CI) | 20 | 26 | 26 | 31 | 26 (21-31) |
CR rate | 7 | 7 | 2 | 15 | 7 (3-15) |
PR rate | 13 | 18 | 25 | 16 | 18 (13-23) |
Response rate by refractory category, % (95% CI) | |||||
Primary refractory | |||||
RR | — | 25 | 27 | 10 | 20 (11-34) |
CR rate | — | 10 | 1 | 2 | 3 (1-11) |
Refractory to second-line or later-line therapy | |||||
RR | 20 | 21 | 20 | 40 | 26 (17-39) |
CR rate | 7 | 5 | 20 | 18 | 10 (5-20) |
Relapse ≤12 mo post-ASCT | |||||
RR | 19 | 35 | — | 39 | 34 (24-45) |
CR rate | 6 | 10 | — | 25 | 15 (6-31) |